Virtual Event | November 9, 2022

Build Vs. Buy: A Pfizer Professional Weighs In

Source: Cytiva

In the cell and gene therapy industry, to build out capabilities or outsource extensively is a difficult decision. Firelli Alonso of Pfizer has some advice.

In October 2022, Outsourced Pharma Live's What’s Driving The Cell & Gene Therapy Outsourcing Capacity Cycle? panelists discussed the identified macro and micro trends impacting deal-making at CDMOs. Exclusive data from BioPlan Associates was also presented. Learn what to be on the lookout for as well as how to prepare and take advantage of (another) "life cycle" in our industry – this time in the cell & gene therapy space.

View the full presentation on-demand here.

VIEW THE VIRTUAL EVENT!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma